Ncardia key facts
- Operator of a biotechnology company intended to provide technologies to expedite drug discovery and development processes.
- Ncardia’s last known valuation is $174.0M.
- It has raised $129.7M; the latest was Later Stage VC ($51.9M) in Sep 2024.
- Notable investors include Noshaq, InnovationQuarter, SambrInvest, Federal Holding and Investment Company (Brussels), Société Régionale d'Investissement de Wallonie — 12 tracked in total.
- Status: Privately Held (backing).
Who backs Ncardia
12+- ·The complete investor list: 12 names
- ·Watch Ncardia: the Monday email on marks, rounds and moves
Ncardia funding rounds
No funding rounds for Ncardia are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Ncardia valuation
Ncardia's last known valuation is $174 million. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.
Ncardia investors
12 investors are on record for Ncardia, including Noshaq, InnovationQuarter, SambrInvest and Federal Holding and Investment Company (Brussels).
About Ncardia
Operator of a biotechnology company intended to provide technologies to expedite drug discovery and development processes. The company uses human induced pluripotent stem cells (hiPSCs) technology to develop predictive human cellular assay systems for safety and efficacy testing of drug candidates as well as enhance cardiovascular and neural drug screening, enabling researchers and drug discovery companies to bring predictive human disease biology and accelerate drug discovery.
- Sector
- Healthcare
- HQ
- Leiden, Netherlands
- Founded
- 2010
- Employees
- 55
- Website
- ncardia.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Ncardia’s last known valuation. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.